Cargando…
Total Synthesis of (±)-Quinagolide: A Potent D(2) Receptor Agonist for the Treatment of Hyperprolactinemia
[Image: see text] A potent dopamine (D(2)) receptor agonist (±)-quinagolide, which is used for the treatment of hyperprolactinemia, was synthesized using the ring closing metathesis (RCM) approach from meta-hydroxybenzaldehyde as the starting material. The key features of this synthesis are pyrolyti...
Autores principales: | Chavan, Subhash P., Kadam, Appasaheb L., Kawale, Sanket A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648496/ https://www.ncbi.nlm.nih.gov/pubmed/31459911 http://dx.doi.org/10.1021/acsomega.9b00903 |
Ejemplares similares
-
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis
por: Zeng, Yanyang, et al.
Publicado: (2023) -
Quinagolide Treatment Reduces Invasive and Angiogenic Properties of Endometrial Mesenchymal Stromal Cells
por: Iampietro, Corinne, et al.
Publicado: (2022) -
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial(†)
por: Busso, Cristiano, et al.
Publicado: (2010) -
Hyperprolactinemia
por: Majumdar, Abha, et al.
Publicado: (2013) -
Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia
por: Su, Junjing, et al.
Publicado: (2017)